Why the FDA’s ‘fast track’ approval process may be hindering cancer therapy around the world

When it comes to cancer drugs, the US Food and Drug Administration is willing to go where other regulators are not. A new study found that the FDA has granted accelerated review and approval to dozens of cancer drugs that were either not reviewed or denied authorisation by NICE and/or the European Medicines Agency (EMA), ...

Already a member?

Login to keep reading.

© 2021 the limbic